Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
5(27.8%)
Phase 3
5(27.8%)
Phase 2
4(22.2%)
Phase 1
4(22.2%)
18Total
N/A(5)
Phase 3(5)
Phase 2(4)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT03789552Phase 3Recruiting

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Role: lead

NCT04993729Phase 3Completed

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Role: lead

NCT04646031Unknown

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Role: lead

NCT04663932Not ApplicableUnknown

Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction

Role: collaborator

NCT05188274Not ApplicableUnknown

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

Role: lead

NCT05183594Not ApplicableUnknown

Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette Syndrome

Role: lead

NCT04285190Not ApplicableWithdrawn

The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19

Role: lead

NCT03552263Phase 2Completed

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Role: lead

NCT03613688Not ApplicableUnknown

Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control

Role: lead

NCT03270787Phase 1Completed

Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness

Role: lead

NCT02388984Phase 3Unknown

Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy

Role: lead

NCT02714608Phase 2Unknown

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Role: lead

NCT01659580Phase 3Completed

Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

Role: lead

NCT01679028Phase 1Completed

Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

Role: lead

NCT00797953Phase 2Completed

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

Role: lead

NCT01501695Phase 3Completed

Phase III Study of 5LGr to Treat Tic Disorder

Role: lead

NCT01473888Phase 1Completed

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

Role: lead

NCT01475279Phase 1Completed

A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin

Role: lead

NCT01107171Phase 2Completed

Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes

Role: collaborator

All 19 trials loaded